Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (33354)	1/12/2010 4:46:22 PM
From: ghmm	1 Recommendation Respond to of 52153

A few brief summaries: BMRN - Biomarin: Revenue for Naglzayme and Kuvan will be on high end of guidance (no mention of Aldurazyme one could take as on low side) and will beat by fair amount on bottom line. Kuvan uptake still accelerating. Bevy of Kuvan studies mentioned (Autism results expected 2H). Amifampridine - March EU launch 10-15 million revenue expected. Plan on meeting with FDA for development pathway. Still considering other indications. PEG PAL-No alteration in study design (but very flexible) "no news good news" Morquio - All patients have completed 1 1mg/kg dose (does trying are .1, 1 and 2). On track to have results mid Q2. DMD - Just started Phase 1. Q3 results. Still looking at possible deals. FOLD - Amicus: Fabry - They expect to complete enrollment (for US trial) in Q4 (6 Month study). Start EU study mid year (doesn't make sense to me wouldn't be surprised if they change priorities unless their financial situation changes). Also mid year start a combo Chaperone/ERT in Fabry Gaucher - Haven't completely given up seems like they will investigate combination with ERT. Pompe- Didn't catch anything mentioned. Preclinical - Announced second area of focus is Alzheimers (not going to enter the clinic anytime soon though at least not in '10). Actelion: I mainly was interested in Bosentan in IPF. No hint at results expect results soon though. I heard some other calls didn't listen as closely to give worthwhile summaries. Disclosure: I have a small position still in Amicus, quite long BMRN and long ITMN (IPF).

To: Biomaven who wrote (33354)	1/12/2010 7:17:30 PM
From: A.J. Mullen	Read Replies (1) \| Respond to of 52153

Illumina I thought I listened to this live, but then I saw the 16% jump in price. I hadn’t noted anything so dramatic, so I went back listen again and made notes. 2009 was a bad year: reagent problem, and stimulus unintended effects – substitution and delay, slow release of funds. Back on track: reagent problem resolved, strong growth of orders and backlog; good results for 4th quarter ,pre-announcing $176 million revenue. Total annual revenue $662M. 8 new array products. Consumer sequencing program launched and San Diego lab approved 20% growth in revenue expected for 2010. No longer giving quarter by quarter estimates. Genotyping costs reduced by factor of 1000 over 8 years. Focusing on the 1000 genome program. Omniexpress 8.4 million markers on a single array just announced – 250% increase in two years. Bovine HD same substrate as omniexpress. 69% increase in Ag business to $91 M dollars annual revenue. Cost to sequence a genome from $1 million in 2007 to $10K now Hiseq 2000 integrating Solexa technology; 2 flow cells, touch-screen interface, remote monitoring. Under $10K for a single human genome. Plug’n’play reagents First customer order for Hiseq 2000. For 128 machines from BGI! First units shipping in Feb. Revenue to be recognized over next three years Improvements in processing the data mean that raw data is processed in more or less realtime, which keeps the data storage manageable. I'm disappointed there wasn't more information on their reasons for selling sequencing direct to the primary consumer. It's a big change to go from selling to big companies and well-supported academics to selling to Joe The Plumber who worries because his second cousin might have had Parkinson's late in life. Ashley (I hold this stock) Wasn’t there an X-prize for this? Or was it for getting the cost per genome down to $1 000?